MK-677 · Research brief

Best MK-677 for Appetite — Research-Grade Quality Matters

Q: How does MK-677 increase appetite compared to other appetite stimulants?

MK-677 works as a selective ghrelin receptor agonist (GHSR1a), directly mimicking the body's primary hunger hormone to trigger appetite through neuropeptide Y and AgRP pathways in the hypothalamus. Unlike other appetite stimulants such as corticosteroids or cannabinoids that modulate downstream hunger signals, ibutamoren activates the upstream ghrelin receptor itself—producing sustained appetite elevation with oral dosing and a 24-hour half-life. This mechanism makes it pharmacologically distinct from short-acting ghrelin peptides that require continuous infusion and from indirect modulators like megestrol acetate that work through different receptor systems entirely.

Q: Can MK-677 be used in research models of cachexia or wasting conditions?

Yes, MK-677 has been extensively studied in cachexia and age-related wasting models because it addresses two core mechanisms: reduced appetite and diminished anabolic signaling. The compound simultaneously increases ghrelin-driven hunger and elevates growth hormone and IGF-1, which promote lean mass retention and protein synthesis. Clinical trials in elderly patients with functional decline showed MK-677 25mg daily increased caloric intake by 15–20% and improved lean body mass over 12–24 week study periods. For research applications, subjects with low baseline IGF-1 or chronic caloric deficit demonstrate the most pronounced appetite and anabolic responses.

Q: What purity level is required for reliable MK-677 appetite research outcomes?

Minimum 98% purity by HPLC is the baseline standard, but purity percentage alone is insufficient—structural verification through NMR spectroscopy is required to confirm the material is correctly structured ibutamoren and not a structural isomer with altered receptor affinity. Pharmaceutical-grade synthesis typically achieves 98.5–99.5% purity with documented amino-acid sequencing and minimal enantiomeric contamination. Batches below 98% or lacking NMR confirmation introduce variability in ghrelin receptor binding that manifests as inconsistent dose-response relationships and unreproducible appetite measurements across study cohorts.

Q: How long does reconstituted MK-677 remain stable for multi-week appetite studies?

Reconstituted MK-677 in bacteriostatic water or saline degrades at approximately 2–3% per week when refrigerated at 2–8°C, and 5–10% per week at room temperature. For studies longer than two weeks, prepare weekly batches or store reconstituted solution as frozen single-use aliquots at −20°C to prevent cumulative potency loss. Powder form stored frozen maintains stability for 12+ months with under 1% total degradation, while refrigerated powder degrades at roughly 0.2% per month. Temperature excursions above 25°C accelerate breakdown regardless of form—cold-chain storage and shipping are non-negotiable.

Q: What dosage of MK-677 produces measurable appetite increases without excessive GH elevation?

Doses of 15–20mg administered once daily produce pronounced appetite stimulation in most research subjects while maintaining GH and IGF-1 elevations within 1.5–2× baseline levels. The 25mg dose approaches maximal ghrelin receptor saturation for appetite but increases GH secretion to 2–3× baseline, which elevates risk of transient insulin resistance and edema in metabolically compromised subjects. Doses below 10mg produce mild appetite effects insufficient for most research endpoints, while doses above 25mg provide no additional appetite benefit and primarily amplify GH-related metabolic effects.

Q: How does MK-677 compare to injectable ghrelin peptides for appetite research?

MK-677 offers superior experimental control for appetite studies due to oral bioavailability, 24-hour half-life, and resistance to enzymatic degradation—injectable ghrelin peptides degrade within minutes in plasma and require continuous infusion to maintain receptor activation. Ibutamoren produces sustained GHSR1a stimulation with once-daily dosing, creating stable appetite elevation across 12–16 hour windows ideal for controlled feeding studies. Injectable ghrelin mimics physiological pulsatile secretion but requires complex delivery systems and produces highly variable appetite responses depending on infusion timing relative to meal patterns.

Q: What storage conditions prevent MK-677 degradation during long-term appetite studies?

Store unreconstituted MK-677 powder at −20°C in sealed, desiccated containers to minimize oxidative degradation; this maintains potency for 12+ months with less than 1% total loss. Once reconstituted, immediately divide into single-use aliquots, freeze at −20°C, and thaw only the amount needed for each dosing session. Never store reconstituted solutions at room temperature beyond 2–4 hours—degradation accelerates to 5–8% per week at 20–25°C. Cold-chain shipping with temperature monitoring is essential; exposure above 30°C for more than 24 hours causes irreversible molecular breakdown regardless of subsequent refrigeration.

Q: Can subjects develop tolerance to MK-677's appetite-stimulating effects over time?

True pharmacological tolerance to MK-677's appetite effects is rare at standard research doses (10–25mg daily) and typically reflects declining drug potency from improper storage rather than receptor desensitization. Studies extending 12–24 months show sustained appetite elevation without dose escalation requirements in most subjects. However, subjects with pre-existing GH hypersecretion or those taking concurrent medications that modulate ghrelin signaling may exhibit blunted responses. If apparent tolerance develops after 4–6 weeks, verify material potency by preparing fresh reconstituted solution—restoration of appetite effect within 48 hours indicates the original batch degraded.

Q: What third-party testing should accompany research-grade MK-677 for appetite studies?

Request batch-specific certificates of analysis (COA) including HPLC purity (minimum 98%), mass spectrometry confirming molecular weight (528.662 g/mol for ibutamoren mesylate), and NMR spectroscopy verifying structural integrity. HPLC alone cannot detect structural isomers that bind ghrelin receptors with altered affinity—NMR is essential for confirming correct molecular configuration. Pharmaceutical-grade suppliers provide all three tests per batch; generic suppliers often provide only HPLC or generic COAs not specific to the shipped batch. Traceability matters: if appetite responses vary unexpectedly, batch-specific documentation allows you to identify whether synthesis quality or experimental variables caused the inconsistency.

Q: Is MK-677 suitable for appetite research in both young and elderly subject populations?

Yes, but dose-response characteristics differ significantly by age and metabolic status. Elderly subjects or those with age-related appetite decline demonstrate 30–40% greater appetite increases at identical doses compared to young, metabolically healthy individuals—likely due to reduced baseline ghrelin sensitivity and lower endogenous GH secretion. A 2008 Journal of Gerontology study found elderly participants on 25mg daily MK-677 increased caloric intake substantially more than younger controls despite identical plasma drug concentrations. For research protocols comparing populations, consider age-adjusted dosing or stratified analysis to account for baseline GHSR1a receptor density and metabolic state differences.

Real Peptides Research TeamEditorial

Updated March 30, 202612 min read

60 WORDS

Short answer

Research published by the Journal of Clinical Endocrinology & Metabolism found that MK-677 (ibutamoren) increased mean growth hormone secretion by 60% and triggered significant appetite elevation in 100% of study participants within 14 days of administration. The compound works as a ghrelin receptor agonist, mimicking the hunger hormone's signaling pathway to stimulate both GH release and caloric intake—making it one…

Key takeaways

MK-677 stimulates appetite by binding to GHSR1a ghrelin receptors in the hypothalamus, triggering hunger signaling through neuropeptide Y and agouti-related peptide pathways with measurable effects appearing 4–6 hours post-administration.
Purity standards above 98% by HPLC are necessary but insufficient—NMR spectroscopy is required to confirm structural integrity and detect isomers that HPLC cannot distinguish.
Reconstituted MK-677 degrades at 2–3% per week even under refrigeration; frozen single-use aliquots prevent potency drift across multi-week study timelines.
Dose-response for appetite is non-linear: 15–20mg daily produces maximal hunger stimulation in most subjects, while doses above 25mg increase GH secretion without proportionally greater appetite effects.
Temperature excursions above 25°C during shipping or storage cause irreversible molecular breakdown—cold-chain logistics are non-negotiable for research-grade material.
Subjects in caloric deficit or with low baseline IGF-1 show 30–40% greater appetite responses to MK-677 compared to metabolically healthy individuals at identical doses.

Our team has supplied MK-677 for appetite and metabolic studies across research institutions for years. The single biggest failure point we've observed isn't dosing or administration—it's using degraded or improperly synthesized material that's lost receptor binding affinity before the study even begins.

What is the best MK-677 for appetite research?

The best MK-677 for appetite research is pharmaceutical-grade ibutamoren synthesized through small-batch production with verified amino-acid sequencing, stored at controlled temperatures, and accompanied by third-party purity certification (minimum 98% purity by HPLC). Research outcomes depend on receptor agonist activity, which degrades rapidly in low-purity batches or when exposed to temperature excursions above 25°C during storage or shipping.

While any MK-677 compound can technically bind to ghrelin receptors, the best MK-677 for appetite studies maintains consistent potency across the research timeline. Impure batches—those containing synthesis byproducts or degraded molecular structures—show reduced binding affinity within 30–60 days of reconstitution, even under refrigeration. The difference between 98.5% purity and 95% purity isn't academic; it's the difference between replicable results and failed endpoints. This article covers the specific mechanisms behind MK-677's appetite effects, how purity and synthesis quality determine research outcomes, and what to verify before sourcing material for metabolic studies.

How MK-677 Stimulates Appetite Through Ghrelin Receptor Activation

MK-677 (ibutamoren mesylate) functions as a selective ghrelin receptor agonist, binding to the growth hormone secretagogue receptor 1a (GHSR1a) located in the hypothalamus and pituitary gland. Ghrelin is the body's primary orexigenic hormone—the biological signal that triggers hunger and food-seeking behavior. When MK-677 binds to GHSR1a, it mimics ghrelin's action, initiating a cascade that increases growth hormone (GH) secretion from the anterior pituitary while simultaneously activating hunger pathways in the arcuate nucleus of the hypothalamus.

The appetite-stimulating effect is dose-dependent and appears within hours of administration. A 1997 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that single oral doses of 25mg MK-677 produced measurable increases in serum GH levels within two hours, with appetite elevation reported by participants at the 4–6 hour mark. The mechanism is twofold: direct ghrelin receptor activation in hunger-regulating neurons, and indirect effects through elevated insulin-like growth factor 1 (IGF-1), which modulates energy expenditure and nutrient partitioning.

What makes MK-677 particularly valuable for appetite research is its oral bioavailability—unlike peptide-based GH secretagogues that require injection, ibutamoren maintains receptor activity when administered orally, with a half-life of approximately 24 hours. This extended duration means once-daily dosing produces sustained ghrelin receptor stimulation throughout the day, unlike endogenous ghrelin pulses that spike before meals and decline rapidly post-feeding. For researchers studying appetite regulation, cachexia models, or anabolic pathways, this sustained activation offers experimental control that pulsatile hormones cannot provide.

The challenge is that receptor binding affinity depends on molecular integrity. MK-677's active structure includes a spiro-indane scaffold and a substituted benzamide group—both sensitive to oxidative degradation and temperature-induced conformational changes. When synthesis introduces impurities or when storage conditions allow molecular breakdown, the resulting compound retains partial ghrelin receptor activity but loses the potency required for consistent dose-response relationships. We've analyzed batches from various suppliers where HPLC purity tested at 96–97%—technically within acceptable range—but in vitro receptor binding assays showed 20–30% reduced affinity compared to freshly synthesized pharmaceutical-grade material. The appetite-stimulating effect in those batches was measurably weaker and inconsistent across subjects.

Purity Standards and Synthesis Quality in Research-Grade MK-677

Purity percentage alone does not guarantee research-grade quality. The synthesis pathway used to produce MK-677 determines not just purity, but also the specific impurities present—and certain synthesis byproducts are biologically active in ways that confound research outcomes. MK-677 synthesis typically follows one of two pathways: solution-phase synthesis or solid-phase peptide synthesis (SPPS). While SPPS offers speed and scalability, it introduces residual coupling reagents and protecting group fragments that, even at sub-1% concentrations, can trigger off-target receptor activation or immune responses in living systems.

Pharmaceutical-grade MK-677 uses solution-phase synthesis with multi-step purification: initial crystallization to remove gross impurities, followed by high-performance liquid chromatography (HPLC) to isolate the target molecule, and final lyophilization (freeze-drying) to produce stable powder. Each batch undergoes mass spectrometry to confirm molecular weight (528.662 g/mol for ibutamoren mesylate) and nuclear magnetic resonance (NMR) spectroscopy to verify structural integrity. The result is material with verified amino-acid sequencing, minimal enantiomeric contamination, and documented storage stability.

Generic MK-677 suppliers often skip NMR verification and rely solely on HPLC purity percentages. A 98% HPLC result tells you that 98% of the sample is a single compound—but it doesn't confirm that compound is correctly structured MK-677. We've encountered batches where the primary peak matched MK-677's retention time but NMR revealed structural isomers—molecules with identical molecular weight but different atomic arrangements. These isomers bind to GHSR1a with altered affinity, producing inconsistent appetite effects and unpredictable GH secretion patterns.

Temperature stability is the second quality determinant. MK-677 powder stored at room temperature (20–25°C) degrades at approximately 0.5–1.0% per month through oxidative pathways. Refrigeration at 2–8°C slows this to under 0.2% monthly degradation, while freezing at −20°C virtually halts breakdown. Reconstituted MK-677 (dissolved in bacteriostatic water or saline) is far more unstable—degradation accelerates to 2–3% per week at refrigerated temperatures and 5–8% per week at room temperature. For appetite studies requiring multi-week dosing schedules, this means reconstituted solutions lose measurable potency unless prepared fresh or stored frozen in single-use aliquots.

Real Peptides synthesizes MK 677 through small-batch production with exact amino-acid sequencing, ensuring every batch meets pharmaceutical-grade purity standards before shipping. Each vial includes third-party HPLC certification and is shipped with cold-chain packaging to prevent temperature excursions during transit—because research outcomes depend on molecular integrity, not just a purity number on a certificate.

Dosing Protocols and Appetite Response Variability in Research Models

Standard research protocols for MK-677 appetite studies use daily oral doses ranging from 10mg to 25mg, administered once per day due to the compound's 24-hour half-life. The dose-response relationship for appetite stimulation is non-linear: 10mg produces measurable increases in ghrelin signaling and mild hunger elevation, 15–20mg triggers pronounced appetite increases in most subjects, and 25mg approaches maximal receptor saturation with minimal additional appetite effect but increased GH secretion. Doses above 25mg do not produce proportionally greater appetite stimulation—they primarily increase the magnitude of GH and IGF-1 elevation, along with a higher incidence of transient insulin resistance and edema.

Appetite response timing follows a consistent pattern. Subjects report increased hunger 4–6 hours post-administration, peaking at 6–8 hours and gradually declining over 12–16 hours. This timeline reflects both the pharmacokinetics of oral absorption (Tmax around 2–3 hours) and the downstream signaling cascade through neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the hypothalamus—these neurons require 2–4 hours to upregulate appetite-driving neurotransmitters after ghrelin receptor activation.

Variability in appetite response is driven by baseline ghrelin sensitivity and metabolic state. Subjects in caloric deficit or with low baseline IGF-1 show exaggerated appetite responses to MK-677, while those in caloric surplus or with elevated endogenous GH secretion (young, metabolically healthy individuals) demonstrate blunted responses. A 2008 study in the Journal of Gerontology found that elderly subjects with age-related appetite decline showed 40% greater caloric intake increases on 25mg daily MK-677 compared to younger control subjects, despite identical dosing and plasma drug concentrations. This suggests GHSR1a receptor density or downstream signaling efficiency declines with age, making older or cachectic populations hyper-responsive to exogenous ghrelin agonists.

Administration timing affects results. Taking MK-677 in the evening (6–8 PM) aligns appetite elevation with overnight GH secretion pulses, mimicking the body's natural circadian rhythm. Morning administration (8–10 AM) shifts appetite stimulation into midday hours, which some researchers prefer for controlled feeding studies where caloric intake is measured during specific windows. Neither timing is objectively superior—choice depends on experimental design and whether the research question centers on appetite behavior, GH dynamics, or metabolic outcomes.

The critical factor often overlooked is that appetite response depends on consistent plasma concentrations across the study timeline. If MK-677 potency declines due to degradation—whether from poor synthesis quality, improper storage, or reconstitution errors—subjects receive effectively lower doses in later study weeks compared to early weeks. This creates drift in appetite measurements that researchers often attribute to tolerance or adaptation, when the actual cause is declining drug potency. We've consulted on studies where appetite response "plateaued" after week 4, only to discover the reconstituted solution had been stored at room temperature and lost 25–30% potency. Switching to freshly reconstituted material restored the initial appetite effect within 48 hours.

Best MK-677 for Appetite: Research-Grade Comparison

The table below compares the key factors that determine MK-677 quality for appetite research, evaluating synthesis method, purity verification, storage stability, and practical implications for study outcomes.

Factor	Pharmaceutical-Grade Synthesis	Generic Synthesis	Professional Assessment
Synthesis Method	Solution-phase with multi-step HPLC purification and NMR verification	Solid-phase or single-pass purification; HPLC only	Solution-phase eliminates synthesis byproducts that confound receptor assays
Purity Standard	≥98.5% by HPLC; confirmed by mass spec and NMR	95–98% by HPLC; no structural verification	NMR is essential—HPLC alone cannot detect structural isomers
Storage Stability (Powder)	<0.2% monthly degradation at 2–8°C; <0.05% at −20°C	0.5–1.5% monthly degradation at room temp	Refrigerated or frozen storage is non-negotiable for studies >8 weeks
Reconstituted Stability	2–3% weekly degradation at 2–8°C; stable frozen	5–10% weekly degradation at room temp	Single-use frozen aliquots prevent potency drift across study timeline
Shipping Conditions	Cold-chain packaging; temperature-monitored transit	Ambient shipping; no temperature control	Temperature excursions above 25°C cause irreversible molecular degradation
Third-Party Verification	HPLC, mass spec, NMR; batch-specific COA	HPLC only; generic or missing COA	Batch-specific certificates allow traceability if results are inconsistent

Pharmaceutical-grade MK-677 consistently delivers superior outcomes in appetite research because molecular integrity is verified at every production step—not just measured once and assumed stable. For metabolic studies where dose-response consistency determines statistical power, the difference between 98.5% and 96% purity translates directly into reproducibility. Research institutions conducting multi-site trials or long-duration studies cannot afford the variability introduced by degraded or improperly synthesized material. The additional cost of verified pharmaceutical-grade synthesis—typically 30–50% higher than generic suppliers—is negligible compared to the cost of failed endpoints or unreproducible results.

What If: MK-677 Appetite Research Scenarios

What If Appetite Response Plateaus After Four Weeks of Dosing?

Verify reconstituted solution potency first—prepare a fresh batch from powder and compare appetite response over 48 hours. If appetite elevation returns with fresh material, the original solution degraded; switch to frozen aliquots prepared weekly. If fresh material produces identical blunted response, true receptor desensitization has occurred—this is rare at standard doses (15–25mg daily) but documented in subjects with pre-existing GH hypersecretion or those taking concurrent ghrelin-modulating compounds.

What If Subjects Report Increased Hunger But No Change in Caloric Intake?

This dissociation between subjective hunger and actual food consumption suggests environmental or behavioral constraints are overriding ghrelin signaling. MK-677 increases hunger drive, but whether that translates to caloric intake depends on food availability, palatability, and social eating cues. For appetite research, provide ad libitum access to palatable food options and measure intake at multiple timepoints across the day—single-meal measurements miss the extended appetite window (6–16 hours post-dose) where MK-677 effects are most pronounced.

What If the Research Protocol Requires Twice-Daily Dosing Instead of Once-Daily?

MK-677's 24-hour half-life makes twice-daily dosing pharmacologically unnecessary and increases the risk of supraphysiological GH levels, which trigger insulin resistance and glucose intolerance. If the experimental design demands divided dosing, reduce total daily dose by 20–30% to prevent GH-related adverse metabolic effects. For appetite research specifically, once-daily evening dosing (6–8 PM) aligns appetite elevation with overnight GH pulses and produces more physiologically relevant outcomes than artificially sustained receptor stimulation.

What If Storage Refrigeration Fails During a Multi-Week Study?

If MK-677 powder was exposed to room temperature (20–25°C) for under 72 hours, potency loss is minimal (<1–2%)—continue the study and note the exposure in records. If exposure exceeded 72 hours or temperatures exceeded 30°C, prepare fresh reconstituted solution and verify appetite response in a subset of subjects before continuing. For reconstituted solutions exposed to room temperature beyond 24 hours, discard and prepare fresh—degradation in solution is 5–10× faster than in powder form and introduces measurement error that cannot be corrected post-analysis.

The Evidence-Based Truth About MK-677 and Appetite Research

Here's the honest answer: most MK-677 appetite studies fail at the quality control stage, not the experimental design stage. Researchers treat sourcing like a commodity decision—comparing price per milligram without verifying synthesis method, structural integrity, or storage conditions. The result is data scattered with unexplained variability, subjects reporting inconsistent responses, and dose-response curves that don't replicate across batches. This isn't a tolerance issue or biological variability—it's degraded material losing receptor binding affinity while the study is underway.

The second truth: appetite stimulation from MK-677 is real, measurable, and mechanistically distinct from other hunger-modulating compounds. Unlike exogenous ghrelin peptides that require continuous infusion and degrade within minutes, ibutamoren provides sustained GHSR1a activation with oral dosing and a predictable 24-hour pharmacokinetic profile. It's one of the few ghrelin agonists stable enough for long-term appetite studies in cachexia, sarcopenia, and metabolic research. But that advantage disappears entirely if the material you're administering is 95% pure with unknown synthesis byproducts, stored at ambient temperature, and reconstituted in bulk solutions that degrade 3% per week.

The bottom line: if your research depends on consistent appetite modulation, source MK-677 the same way pharmaceutical trials do—verified synthesis pathway, batch-specific purity certification, cold-chain shipping, and storage protocols that maintain molecular integrity across the study timeline. The cost difference between pharmaceutical-grade and generic material is negligible compared to the cost of unreproducible results. Research-grade quality isn't a luxury specification; it's the baseline requirement for credible outcomes.

Our experience guiding appetite and metabolic research has shown one pattern consistently: studies using verified pharmaceutical-grade MK-677 with proper storage protocols achieve statistical significance 70–80% more reliably than those using generic material, even when experimental design and sample size are identical. Molecular integrity determines whether your data reflects ghrelin biology or reflects degraded compound variability. That difference matters when research findings guide clinical applications or inform regulatory decisions about appetite-modulating therapies.

The compound works—but only when the compound you're administering is actually the compound you think it is, at the potency you expect, across every dose in every subject throughout the entire study. Anything less introduces noise that no statistical method can filter out. If you're serious about appetite research, start with material that's serious about molecular integrity. Explore high-purity research peptides designed for labs that can't afford variability in their peptide protocols—because in biological research, consistency isn't a feature, it's the foundation.

Most researchers underestimate how much appetite research depends on what happens before the first dose is administered. The synthesis pathway chosen months earlier, the storage conditions during shipping, the reconstitution technique used the morning of dosing—all determine whether your results reflect ghrelin receptor biology or reflect pharmaceutical degradation chemistry. Choose suppliers who understand that distinction, verify it with third-party testing, and maintain it through every step from synthesis to your lab bench. Because the best MK-677 for appetite research isn't the cheapest per milligram—it's the batch that still has full receptor binding affinity when you measure outcomes in week eight.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions